戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ly expressed in melanoma cells with high vs. low metastatic abilities.
2 vels in human colon cancer cells of high and low metastatic ability were manipulated via expression o
3 C-3, PANC-1, and MiaPACA-2, which have no or low metastatic activity, and PATU-8988S, AsPC-1, SUIT-2
4 s of two isogenic canine OS cell lines, POS (low metastatic) and HMPOS (highly metastatic), under nor
5 noma variants, SBC-2 (nonmetastatic), A375P (low metastatic), and A375SM (high metastatic), by increa
6 l implanted with high metastatic (B16F10) or low metastatic (B16F1) melanoma cells.
7 growth factor receptor 2 (HER2)-negative or -low metastatic breast cancer (MBC) benefit from HER2-tar
8                           Patients with HER2-low metastatic breast cancer (mBC), defined as an immuno
9 acy in previously treated patients with HER2-low metastatic breast cancer (mBC), marking a new therap
10                The approval of T-DXd in HER2-low metastatic breast cancer was based on statistically
11 an epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer who are eligible for trastu
12 ase of a patient with hormone-sensitive HER2 low metastatic breast cancer who underwent circulating t
13  price, T-DXd is not cost effective for HER2-low metastatic breast cancer.
14 ter prior chemotherapy in patients with HER2-low metastatic breast cancer.
15 erapy specifically for the treatment of HER2-low metastatic breast cancer.
16 st cancer; (iii) clinical management of HER2-low metastatic breast cancer; and (iv) clinical trial de
17 ion promoted long-term survival of mice with low metastatic burden and induced a tumor-specific prote
18 se with oligometastatic disease, in whom the low metastatic burden in particular might be treatable w
19  of prostate RT was greater in patients with low metastatic burden with only nonregional lymph nodes
20 ts with newly diagnosed prostate cancer with low metastatic burden, but not those with high-burden di
21 evels, which predicts their inherent high or low metastatic capacity.
22 ities of IL-8 and remain unmethylated in the low metastatic cell lines where the IL-8 gene is relativ
23 erences in IL-8 release between the high and low metastatic cell lines.
24 RNA transcripts than parental PC-3M cells or low metastatic cells, which displayed a heterogeneous pa
25 d2 and low SEMA3F levels compared with their low metastatic counterparts.
26 gments (OPN-5 kDa, residues 167-210) induced low-metastatic HCC cellular invasion via CD44 receptors,
27 e in vivo behavior of a variety of high- and low-metastatic human and mouse cancer cell lines and the
28 31 cells than in distal non-tumor tissue and low-metastatic MCF-7 cells, respectively.
29 ich was abrogated by silencing CCN1/CYR61 in low metastatic melanoma cells.
30 a cell lines that have been characterized as low metastatic or high metastatic, respectively, for AP-
31                  Our results reveal that the low metastatic osteosarcoma cells display larger spreadi
32 ly metastatic cells were compared with their low metastatic parental cells (686LN-Ps), we found that
33 GF, type IV collagenase, and mdr-1 mRNA than low metastatic parental cells in the same site.
34 3 to a 2-fold greater extent than mucin from low-metastatic parental cell line LS174T.
35 uppressed the growth of Lewis lung carcinoma-low metastatic phenotype metastases in C57BL/6 mice by g
36 d the growth of primary Lewis lung carcinoma-low metastatic phenotype tumors.
37 ular and cell surface galectin 3 in cells of low metastatic potential (LS174T).
38 ith each one comprising a parental line with low metastatic potential and its experimentally selected
39 ap and DU145 prostate cancer cell lines with low metastatic potential but overexpressed in high metas
40 nk4a/p16 locus (HP mice) form melanomas with low metastatic potential in response to UV irradiation.
41 dence that suggests donors with melanomas of low metastatic potential may provide an opportunity to s
42 quate tumor control for iris melanoma with a low metastatic potential of 1% at 7 years.
43 mors primarily located in the iris have very low metastatic potential, even with ciliary body involve
44 tection of biologically indolent tumors with low metastatic potential.
45 lin E and FAK when compared to tumors with a low metastatic potential.
46 phaM cells produced slow growing tumors with low metastatic potential.
47 atic MDA-MB-435 cells, but not in cells with low metastatic potential.
48 elocity characteristics relative to cells of low metastatic potential.
49  melanomas to prognostic subgroups: class 1 (low metastatic risk) and class 2 (high metastatic risk).
50 s are associated with prolonged survival and low metastatic risk, SF3B1-mutated tumors are associated
51 mall renal masses are indolent and possess a low metastatic risk.
52 1b+) cells rapidly and transiently converted low metastatic SCA1- cells into highly metastatic SCA1+
53 n had a modest impact on cancer incidence in low metastatic stages but significantly reduced the like
54                            REST knockdown in low-metastatic T47D cells and nontumorigenic MCF12A cell
55    Furthermore, ectopic expression of Id2 in low metastatic tumor cells downregulated SEMA3F and, as
56     In contrast, no increase was observed in low-metastatic TXM-40 cells.